Clinical trials
Sarcoma trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 3 |
| 2004 | 4 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 10 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 4 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 40 |
| Recruiting | 11 |
| Active, not recruiting | 10 |
| Terminated | 10 |
| Unknown status | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Children's Oncology Group | 19 |
| National Cancer Institute (NCI) | 12 |
| Eli Lilly and Company | 5 |
| Bayer | 2 |
| Hoffmann-La Roche | 2 |
| ImmunityBio, Inc. | 2 |
| MacroGenics | 2 |
| Turning Point Therapeutics, Inc. | 2 |
| Actym Therapeutics, Inc. | 1 |
| Alaunos Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sarcoma | 75 |
| Ovarian Neoplasms | 15 |
| Neuroectodermal Tumors, Primitive, Peripheral | 14 |
| Osteosarcoma | 14 |
| Breast Neoplasms | 13 |
| Colorectal Neoplasms | 13 |
| Neuroblastoma | 13 |
| Rhabdomyosarcoma | 13 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Melanoma | 12 |
Trials
Showing 26 to 50 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.